Navigation Links
Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
Date:5/14/2008

MISSISSAUGA, ON, May 14 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) today announced that its President and CEO, Chris Waddick, will present a Company overview at the Rodman & Renshaw 5th Annual Global Healthcare Conference in Monte Carlo, at 12:30 p.m. local time (6:30 a.m. ET) on Monday, May 19, 2008.

A live webcast of the presentation can be accessed through Vasogen's website at http://www.vasogen.com. An archived replay will also be available following the presentation.

About Vasogen:

Vasogen is a biotechnology company engaged in the research and development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders.

Certain statements contained in this press release, the upcoming presentation and webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of the Celacade(TM) System or our VP Series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
2. Vasogen Announces Implementation of Strategic Restructuring Plan
3. Vasogen Announces First Quarter 2008 Results
4. Vasogen to Webcast its Annual Meeting
5. Vasogen Provides Update on ACCLAIM II Program
6. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
7. Vasogens Research Published in European Journal of Neuroscience
8. The Lancet Publishes Vasogens ACCLAIM Results
9. Vasogen Announces 2007 Year-End Results
10. Vasogen to Conduct Year-end 2007 Conference Call
11. Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... NxGen MDx announced today that it brought its NxGen Informed ... been able to improve customer service through shortened turnaround times and at ... , CEO of NxGen MDx. ... A decrease in turnaround times by ... job opportunities at the Grand Rapid headquarters. The NxGen Informed ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... studies. A microbiome impact grant award has been made to Dr. Renato Polimanti ... smoking and drinking on the oral microbiome. Grant proposals have been vetted by ...
(Date:12/2/2016)...  The Multiple Myeloma Research Foundation (MMRF) today announced ... SM —the largest and most comprehensive study driving new ... be presented at the 58 th American Society ... San Diego from December 3-6. The ... well as identify pathways and targets for new drug ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
Breaking Biology Technology:
(Date:6/27/2016)... Research and Markets has announced the addition ... to their offering. The report ... to grow at a CAGR of 12.28% during the period 2016-2020. ... in-depth market analysis with inputs from industry experts. The report covers ... The report also includes a discussion of the key vendors operating ...
(Date:6/20/2016)... -- Securus Technologies, a leading provider of civil ... investigation, corrections and monitoring announced that after exhaustive ... the final acceptance by all three (3) Department ... (MAS) installed. Furthermore, Securus will have contracts for ... October, 2016. MAS distinguishes between legitimate wireless device ...
(Date:6/7/2016)... TORONTO , June 7, 2016  Syngrafii ... begun a business relationship that includes integrating Syngrafii,s ... pilot branch project. This collaboration will result in ... for the credit union, while maintaining existing document ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
Breaking Biology News(10 mins):